Business

Former L'Oréal President Jim Morrison, Chief Executive Officer of Emergent Health Reports Quarter over Quarter Revenue Increase of Over 2300%

Former L'Oréal President Jim Morrison, Chief Executive Officer of Emergent Health Reports Quarter over Quarter Revenue Increase of Over 2300%.

articleEmergent Health Corp.May 16, 20235/company/emergent-health-corp/news/former-loreal-president-jim-morrison-chief-executive-officer-of-emergent-health-reports-quarter-over-quarter-revenue-increase-of-over-2300percent
Former L'Oréal President Jim Morrison, Chief Executive Officer of Emergent Health Reports Quarter over Quarter Revenue Increase of Over 2300%

About this update from Emergent Health Corp.

[{"type":"text","content":"New York, NY / May 16, 2023 / Emergent Health Corp. (OTC PINK: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced revenues of $340,531 for the quarter ended March 31, 2023, as compared to $14,267 for the quarter ended March 31, 2022, an increase of over 2300%. The financial statement can be viewed in its entirety at https://www.otcmarkets.com/stock/EMGE/disclosure.Jim Morrison, former L'Oréal President and Emergent’s full time CEO stated \"Q1 was a good starting point for the 'new look' EMGE. You will see the effect of many of our new business initiatives as we move into the second quarter and throughout the year. We are on track for 2023 to be a very good year.\"Emergent believes it will continue increasing its revenues quarter over quarter as it expands its business internally and externally through acquisition.Recent Developments:On May 11, 2023, announced that its subsidiary Evolutionary Biologics, Inc. (EvoBio), a developer, manufacturer and distributor of private label regenerative medicine products and branded state-of-the-art biologic products, created in a pharmaceutical grade laboratory and manufacturing facility has executed a Product Manufacturing Agreement with a distributor of medical devices that desires to market a MSC Exosome product from EvoBio as a private label on an exclusive basis. The Company believes the new relationship will generate at least $2 million in new revenue. The press release can be viewed in its entirety    here.On May 9, 2023, announced that it has engaged BF Borgers CPA PC, a full-service audit, tax, accounting, and advisory firm, as its Public Company Accounting Oversight Board (PCAOB) qualified auditor to audit the Company’s financial statement for the two-year period ending December 31st, 2022 according to Generally Accepted Accounting Principles (GAAP). GAAP is the accounting standard adopted by the Securities and Exchange Commission (SEC) and is the default accounting standard used by companies based in the United States. The press release can be viewed in its entirety here.On May 4, 2023, announced the execution of an Engagement Letter with Boustead Securities LLC. to act as exclusive financial advisor with respect to a planned corporate financing transaction including the private placement of securities (pre-IPO Financ...

More updates from Emergent Health Corp.